Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
Abstract Background To conduct an indirect treatment comparison of patients with high-volume mHSPC and a cost analysis between Abi-ADT and Doc-ADT therapies in China. Methods The Bucher technique for indirect treatment comparison was used. A cost analysis was conducted from both healthcare and patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-12-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12962-019-0193-4 |
| _version_ | 1819132512944783360 |
|---|---|
| author | Xin Hu Shuli Qu Xingxing Yao Chaoyun Li Yanjun Liu Jianye Wang |
| author_facet | Xin Hu Shuli Qu Xingxing Yao Chaoyun Li Yanjun Liu Jianye Wang |
| author_sort | Xin Hu |
| collection | DOAJ |
| description | Abstract Background To conduct an indirect treatment comparison of patients with high-volume mHSPC and a cost analysis between Abi-ADT and Doc-ADT therapies in China. Methods The Bucher technique for indirect treatment comparison was used. A cost analysis was conducted from both healthcare and patient perspectives. Results The indirect treatment comparison demonstrated no significant difference in PFS for Abi-ADT versus Doc-ADT (HR: 0.84, 95% CI 0.66–1.07). Doc-ADT therapy costs less than Abi-ADT, with potential savings of up to RMB 887,057 per patient from the healthcare perspective and RMB 226,210 per patient from the patient perspective. Conclusions No significant differences in PFS between Doc-ADT and Abi-ADT therapy for patients with high-volume mHSPC. Doc-ADT therapy is a cost-saving alternative to Abi-ADT in China. |
| first_indexed | 2024-12-22T09:32:35Z |
| format | Article |
| id | doaj.art-6d456d5d006d47b9a9156a43bf3fd83d |
| institution | Directory Open Access Journal |
| issn | 1478-7547 |
| language | English |
| last_indexed | 2024-12-22T09:32:35Z |
| publishDate | 2019-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj.art-6d456d5d006d47b9a9156a43bf3fd83d2022-12-21T18:30:54ZengBMCCost Effectiveness and Resource Allocation1478-75472019-12-0117111010.1186/s12962-019-0193-4Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysisXin Hu0Shuli Qu1Xingxing Yao2Chaoyun Li3Yanjun Liu4Jianye Wang5Department of Pharmacy, Beijing HospitalReal World Solutions, IQVIAHealth Economics & Outcome Research, SanofiHealth Economics & Outcome Research, SanofiReal World Solutions, IQVIADepartment of Urology, Beijing HospitalAbstract Background To conduct an indirect treatment comparison of patients with high-volume mHSPC and a cost analysis between Abi-ADT and Doc-ADT therapies in China. Methods The Bucher technique for indirect treatment comparison was used. A cost analysis was conducted from both healthcare and patient perspectives. Results The indirect treatment comparison demonstrated no significant difference in PFS for Abi-ADT versus Doc-ADT (HR: 0.84, 95% CI 0.66–1.07). Doc-ADT therapy costs less than Abi-ADT, with potential savings of up to RMB 887,057 per patient from the healthcare perspective and RMB 226,210 per patient from the patient perspective. Conclusions No significant differences in PFS between Doc-ADT and Abi-ADT therapy for patients with high-volume mHSPC. Doc-ADT therapy is a cost-saving alternative to Abi-ADT in China.https://doi.org/10.1186/s12962-019-0193-4Prostate cancerDocetaxelAbirateroneCost analysis |
| spellingShingle | Xin Hu Shuli Qu Xingxing Yao Chaoyun Li Yanjun Liu Jianye Wang Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis Cost Effectiveness and Resource Allocation Prostate cancer Docetaxel Abiraterone Cost analysis |
| title | Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis |
| title_full | Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis |
| title_fullStr | Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis |
| title_full_unstemmed | Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis |
| title_short | Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis |
| title_sort | abiraterone acetate and docetaxel with androgen deprivation therapy in high volume metastatic hormone sensitive prostate cancer in china an indirect treatment comparison and cost analysis |
| topic | Prostate cancer Docetaxel Abiraterone Cost analysis |
| url | https://doi.org/10.1186/s12962-019-0193-4 |
| work_keys_str_mv | AT xinhu abirateroneacetateanddocetaxelwithandrogendeprivationtherapyinhighvolumemetastatichormonesensitiveprostatecancerinchinaanindirecttreatmentcomparisonandcostanalysis AT shuliqu abirateroneacetateanddocetaxelwithandrogendeprivationtherapyinhighvolumemetastatichormonesensitiveprostatecancerinchinaanindirecttreatmentcomparisonandcostanalysis AT xingxingyao abirateroneacetateanddocetaxelwithandrogendeprivationtherapyinhighvolumemetastatichormonesensitiveprostatecancerinchinaanindirecttreatmentcomparisonandcostanalysis AT chaoyunli abirateroneacetateanddocetaxelwithandrogendeprivationtherapyinhighvolumemetastatichormonesensitiveprostatecancerinchinaanindirecttreatmentcomparisonandcostanalysis AT yanjunliu abirateroneacetateanddocetaxelwithandrogendeprivationtherapyinhighvolumemetastatichormonesensitiveprostatecancerinchinaanindirecttreatmentcomparisonandcostanalysis AT jianyewang abirateroneacetateanddocetaxelwithandrogendeprivationtherapyinhighvolumemetastatichormonesensitiveprostatecancerinchinaanindirecttreatmentcomparisonandcostanalysis |